Parainfluenza virus vaccine

Drug Profile

Parainfluenza virus vaccine

Latest Information Update: 09 Jul 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins University; Saint Louis University; sanofi pasteur
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Parainfluenza virus infections

Most Recent Events

  • 24 Dec 1999 Pasteur Mérieux Connaught is now a subsidiary of Aventis and its new name is Aventis Pasteur
  • 22 Jul 1999 A study has been added to the Vaccines and Viral Infections immunogenicity sections
  • 12 Feb 1998 Phase-I clinical trials for Parainfluenza virus infections in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top